Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans TL, Langer CJ: Determinants of Survival in Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapies. Clinical Lung Cancer Jul 2013.
Aggarwal, C: Nab-paclitaxel is a valuable NSCLC therapy option. Community Oncology 10(6), Jun 2013.
Aggarwal C, Dahlberg SE, Hanna N, Kolesar J, Hirsch FR, Ramalingam SS and Schiller JH : Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, IMC-A12, or both for advanced non-small cell lung cancer patients. Journal of Clinical Oncology 31s(abstr 8106), Jun 2013.
Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans TL, Langer CJ: Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist? Lung Cancer Jun 2013.
Lustgarten DS, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer CJ, Inghilleri S, Stella G, Albelda SM
: Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma
Journal of Thoracic Oncology
Volume 8 (4): 469–477, Apr 2013.
Aggarwal, C and Langer, CJ: Recent advances in the management of advanced Non Small Cell Lung Cancer. Community Oncology 10(4), Apr 2013.
Aggarwal C, Meropol N J, Punt C J, Iannotti N, Saidman B H, Sabbath K D, Gabrail N Y, Picus J, Morse M A, Mitchell E, Miller M C, Cohen S J: Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 24(2): 420-8, Feb 2013.
Aggarwal C, Ranganathan A, Lustgarten DS et al: Circulating Tumor Cells In Patients With Small Cell Lung Cancer: A Marker Of Disease Burden, Therapeutic Response, And Predictor Of Disease Relapse. Journal of Thoracic Oncology Sep 2012.
Brady A, McNeill JD, Judy B, Evans T, Cohen RB, Langer C, Vachani A AND Aggarwal C: Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer patients treated with first-line chemotherapy. Journal of Clinical Oncology Supplement Jun 2012.
Ranganathan A, Schwed-Lustgarten D, Aggarwal C et al: Circulating tumor cells in patients with small cell lung cancer: a marker of disease burden, therapeutic response, and predictor of disease relapse Journal of Clinical Oncology Supplement Jun 2012.
back to top
Last updated: 07/14/2016
The Trustees of the University of Pennsylvania